Abstract

Cladribine induces protracted remissions in patients with hairy cell leukemia (HCL). However, many long-term responders ultimately relapse. We sought to determine if long-term complete responders subsequent to a single seven-day course of cladribine were without minimal residual disease (MRD), and potentially cured of HCL. From the 358-person Scripps Clinic cladribine database, we identified 19 patients in continuous and complete hematologic response: median age, 75 years; median time from diagnosis,...